Tuesday, October 17th
13:30 – 15:00 → Venue: Darwin

**DNDi’s session**

**Phase II/III results for fexinidazole, the first oral treatment for human African trypanosomiasis (HAT)**

**Organizer:** Nathalie Strub-Wourgaft, Medical Director, Drugs for Neglected Diseases initiative (DNDi)

**Chair:** José Ramon Franco, NTD department, WHO

**Speakers:**
- **Introduction**
  José Ramon Franco, NTD department, WHO
- **Developing treatments for sleeping sickness: DNDi’s R&D strategy**
  Nathalie Strub-Wourgaft, Medical Director, DNDi
- **Results from the pivotal trial of fexinidazole: non-inferiority shown to the gold standard NECT**
  Antoine Tarral, Head of HAT clinical programme, DNDi
- **The efficacy of fexinidazole in children and stage 1 patients**
  Clélia Bardonneau, Senior Clinical Project Manager, DNDi
- **Film: ‘The Last Mile’**
- **Structured discussion 1:** Working together across continents to organize and run clinical trials in remote areas
  Wilfried Mutombo Kalonji, Project Coordinator HAT, DNDi
  Olaf Valverde Mordt, Medical Manager HAT, DNDi
- **Structured discussion 2:** The potential impact of fexinidazole on the global strategy to eliminate sleeping sickness
  Crispin Lumbala, Director, PNLTHA, DRC
  Pere Perez Simarro, HAT Access Advisor, DNDi

**Poster session**

- **Clinical mentoring via mobile teams – a new approach to visceral leishmaniasis care in resource constrained settings in Africa**

- **Screening the pathogen box and the stasis box to identify compounds inhibiting Madurella mycetomatis growth in vitro and in vivo**
  Lim W, Konings M, Melse Y, Todd M, Perry B, Ioset JR, van de Sande W
Wednesday, October 18th

Oral presentation with a DNDi author

15:30 → Venue: Toucan

Hepatitis C care in resource-constrained settings – Do we have a scalable public health approach anno 2017?

- The innovative R&D model of the Drug for Neglected Diseases initiative (DNDi) to increase access to HCV care in low- and middle-income countries
  Andrieux-Meyer I

Poster session

- The Human African Trypanosomiasis (HAT) Platform
  Mbo F, Valverde O

- Is long lasting insecticide treated bed net able to reduce visceral leishmaniasis incidence? The evidence in Bangladesh
  Chowdhury R, Chowdhury V, Faria S, Dash AP, Bhattacharya SK, Akhter S, Akter S, Argaw D, Bern C, Alvar J, Banu Q

- Projected number of people with onchocerciasis-loiasis co-infection in Africa, 1995-2025
  Vinkeles Melchers NVS, Tekle AH, Coffeng LE, Pion SDS, Zouré HGM, Pedrique B, Boussinesq M, Wanji S, Remme JHF, Stolk WA

Thursday, October 19th

Oral presentations with a DNDi co-author

15:30 → Venue: Toucan

Kala-azar elimination in the Indian subcontinent

- Phlebotomus argentipes Sand Fly control in Bangladesh: A cluster randomized controlled trial

17:00 → Venue: Toucan

International Partnerships and Collaboration

- Building a visceral leishmaniasis data-sharing platform to optimize treatment and inform future research
  Guerin PJ, Otieno M, Alvar J, on behalf of the IDDO VL data platform

Poster session

- Visceral leishmaniasis treatment access – The reality on the ground in Sudan

DNDi

Drugs for Neglected Diseases initiative

15 Chemin Louis-Dunant – 1202 Geneva
Switzerland
Tel: +41 22 906 9230
Fax: +41 22 906 9231
dndi@dndi.org
www.dndi.org

facebook.com/dndi.org
twitter.com/dndi
instagram.com/drugsforneglecteddiseases
Linkedin: linkedin.com/company/dndi
youtube.com/dndiconnect

Subscribe to DNDi’s newsletter:
www.dndi.org/newsletter

Photo credits: Simon Tschiamala-DNDi